论文部分内容阅读
慢性移植物抗宿主病(chronic graft versus host disease,cGVHD)是由移植后异体供者移植物中的T淋巴细胞以受者靶细胞为目标发动的细胞毒攻击,其作为异体造血干细胞移植的主要并发症目前备受关注。Ibrutinib是一种高效的口服不可逆布鲁顿酪氨酸激酶(Bruton’s tyrosine kinase,BTK)抑制剂,目前已用于恶性淋巴细胞瘤的临床治疗,药理学机制发现Ibrutinib可能对cGVHD的预防和发展具有重要作用。本文就近年来Ibrutinib对cGVHD的临床治疗前景、作用靶点和作用机制等方面的研究新进展进行综述。
Chronic graft versus host disease (cGVHD) is a cytotoxic challenge targeting target cells of T lymphocytes in allogeneic donor grafts after transplantation as a primary source of allogeneic hematopoietic stem cell transplantation Complications are currently of concern. Ibrutinib is a highly effective oral inhibitor of irreversible Bruton’s tyrosine kinase (BTK) and has been used in the clinical treatment of malignant lymphoma. The pharmacological mechanism of Ibrutinib is that Ibrutinib may have the potential of preventing and developing cGVHD Important role. This review summarizes recent advances in the clinical treatment of cGVHD by Ibrutinib in recent years.